Segment Reporting (Details) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025 USD ($)	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 USD ($)	Mar. 31, 2024 USD ($)	Sep. 30, 2025 USD ($) segment	Sep. 30, 2024 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment							1
Number of reportable segments | segment							1
Segment Reporting Information [Line Items]
Total revenue	$ 1,752			$ 1,136			$ 4,606	$ 3,291
Total research and development	11,149			8,108			29,081	23,836
General and administrative	8,228			6,280			21,446	20,372
Total operating expenses	19,377			14,388			50,527	44,208
Loss from operations	(17,625)			(13,252)			(45,921)	(40,917)
Other (expense) income :
Interest expense	(1,314)			(29)			(3,856)	(87)
Interest income	207			310			778	843
Other (expense) income, net	(1,319)			1			(1,141)	(13)
Total other (expense) income	(2,426)			282			(4,219)	743
Net loss	(20,051)	$ (14,739)	$ (15,350)	(12,970)	$ (15,280)	$ (11,924)	(50,140)	(40,174)
Collaborative Arrangements
Segment Reporting Information [Line Items]
Total revenue	1,752			1,136			4,606	3,291
Total research and development							1,900	900
Reportable Segment
Segment Reporting Information [Line Items]
Research and development personnel costs	4,353			3,745			12,454	9,590
Facilities and other support costs	864			791			2,665	2,168
Other	726			570			1,870	1,339
Total research and development	11,149			8,108			29,081	23,836
General and administrative	8,228			6,280			21,446	20,372
Total operating expenses	19,377			14,388			50,527	44,208
Loss from operations	(17,625)			(13,252)			(45,921)	(40,917)
Other (expense) income :
Interest expense	(1,314)			(29)			(3,856)	(87)
Interest income	207			310			778	843
Other (expense) income, net	(1,319)			1			(1,141)	(13)
Total other (expense) income	(2,426)			282			(4,219)	743
Net loss	(20,051)			(12,970)			(50,140)	(40,174)
Reportable Segment | OCU400
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	3,616			1,492			7,463	5,190
Reportable Segment | OCU410 and OCU410ST
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	1,373			759			3,675	2,598
Reportable Segment | NeoCart
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	19			104			25	459
Reportable Segment | COVAXIN
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	0			(65)			0	8
Reportable Segment | Inhaled mucosal vaccine platform
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	67			664			399	2,160
Reportable Segment | OCU200
Segment Reporting Information [Line Items]
Research and development expense (excluding acquired in process cost)	131			48			530	324
Reportable Segment | Collaborative Arrangements
Segment Reporting Information [Line Items]
Total revenue	$ 1,752			$ 1,136			$ 4,606	$ 3,291